Navigation Links
Mirus Bio Awarded Grants & Contracts of Over $5 Million

MADISON, Wis., Aug. 23 /PRNewswire/ -- Mirus Bio Corporation today announced that it has been awarded five federal grants and contracts since January of this year totaling $5.4 million. They include:

-- Two Phase II SBIR grants totaling $2.4 million to further develop the

Company's Dynamic PolyConjugates(TM) siRNA delivery platform and

alternative nanoparticle technologies, focused primarily on improving

potency for liver applications;

[Principal Investigators Drs. D. Rozema and S. Wong]

-- One Phase II DOD contract for $1.8 million to optimize the Dynamic

PolyConjugates(TM) siRNA delivery platform for lung delivery and to

develop a treatment against respiratory infections;

[Principal Investigator Dr. H. Herweijer]

-- A Phase I SBIR grant for $0.3 million to improve gene expression

technologies; and

[Principal Investigator Dr. M. Sebestyen]

-- A previously announced Phase II SBIR grant for $0.9 million to develop

improved labeling technologies for microRNA, which is expected to lead

to new research products.

[Principal Investigator Dr. M. Watt]

"Securing this magnitude of support highlights the wide breadth of potential uses for this platform delivery technology and is a tribute to the outstanding cutting edge technology development being done by our research team," commented Jon Wolff, M.D., Mirus Bio's CSO and co-founder. "In this era of heightened competition for federal research grants, we are exceptionally pleased with this outcome and couldn't be more proud of our team as well as the grant procurement management that Dr. Hans Herweijer has provided. These funds are critical to maintaining our leadership position in nucleic acid delivery technologies."

Dynamic PolyConjugates(TM) (DPC) are an enabling platform for the targeted, systemic delivery of small interfering RNA (siRNA), a molecule that triggers a natural cellular process called RNA interference. By selectively silencing the expression of a gene, one can prevent the production of disease-causing proteins. DPCs are comprised of proprietary polymers, masking agents and targeting molecules that are linked to the siRNA payload and shield it as it is injected into the bloodstream. When the DPCs attach to and are taken up by the target cells, they disassemble and release their siRNA cargo so that it becomes functionally available. This technology is currently being optimized for delivery to liver and cancer tissues, and is actively being evaluated by select partners as a therapeutic platform for multiple disease indications.

About Mirus Bio Corporation:

Mirus Bio Corporation is a leader in the fields of RNA interference and gene therapy, based upon its expertise in nucleic acid chemistry and delivery. The company's Dynamic PolyConjugates(TM) technology is being refined as an enabling platform for siRNA therapeutics. In gene therapy, the company is developing novel human therapeutics enabled by its proprietary Pathway IV(TM) hydrodynamic delivery platform. The lead program is a treatment for Muscular Dystrophy, which is being developed collaboratively with Transgene S.A. of Strasbourg, France. Finally, the company currently markets state-of-the-art DNA and siRNA transfection and labeling products to researchers worldwide.

For more information go to:

SOURCE Mirus Bio Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Mirus Bio secures $900K grant to develop research tool
2. Mirus Bio, Pfizer enter multimillion-dollar research agreement
3. Mirus Bio awarded patent on RNA delivery
4. Mirus granted European patent for gene therapy
5. Mirus provides low-cost way to modify genes
6. Mirus announces new method for making antibodies
7. Platypus adds Mirus VP to board of directors
8. Mirus receives $1.26 million SBIR grant to combat anemia
9. Small Tree Communications awarded $2.85M defense contract
10. Alfalight awarded $1.7M from Army Research Lab
11. UW Biomedical Engineering awarded $2.9 million research grant
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... Matthew “Tex” VerMilyea, PhD, ... VerMilyea will oversee all IVF lab procedures as well as continue his ... , “We traveled 7,305 miles to Auckland, New Zealand to bring home a High ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... Global ... and development stages of a new closed system for isolating adipose-derived stem cells. The ... vascular fraction (SVF) of adipose tissue. SVF is a component of the lipoaspirate obtained ...
(Date:11/30/2015)... radiology technique shows promise for helping morbidly obese patients lose ... presented today at the annual meeting of the Radiological Society ... --> --> Gastric artery embolization ... way to stop bleeding in emergency situations, but the idea ... is new. Mubin Syed , M.D., interventional radiologist ...
(Date:11/30/2015)... 30, 2015  Culprits beware, a University at ... Jan Halámek, is taking crime scene fingerprint identification ...   -->   --> ... --> --> Halámek and ... a straightforward concept for identifying whether a culprit ...
Breaking Biology Technology:
(Date:10/29/2015)... Daon, a global leader in mobile biometric ... new version of its IdentityX Platform , IdentityX ... have already installed IdentityX v4.0 and are ... FIDO UAF certified server component as an option ... features. These customers include some of the largest and ...
(Date:10/29/2015)... 29, 2015  Connected health pioneer, Joseph C. ... of technology-enabled health and wellness, and the business opportunities ... The Internet of Healthy Things . Long ... even existed, Dr. Kvedar, vice president, Connected Health, Partners ... delivery, moving care from the hospital or doctor,s office ...
(Date:10/29/2015)... Oct. 29, 2015 Today, LifeBEAM ... partnership with 2XU, a global leader in technical ... smart hat with advanced bio-sensing technology. The hat ... to monitor key biometrics to improve overall training ... the two companies will bring together the most advanced ...
Breaking Biology News(10 mins):